S&P 500   4,145.19
DOW   32,803.47
QQQ   321.75
China July exports rise, with trade surplus at record-high
pixel
Demand for grocery delivery cools as food costs rise
Shift in war's front seen as ships cleared to leave Ukraine
Dems push Biden climate, health priorities toward Senate OK
Dems' climate, energy, tax bill clears initial Senate hurdle
Transit woes mount for Boston's beleaguered subway riders
Shift in war's front seen as grain leaves Ukraine; plant hit
S&P 500   4,145.19
DOW   32,803.47
QQQ   321.75
China July exports rise, with trade surplus at record-high
pixel
Demand for grocery delivery cools as food costs rise
Shift in war's front seen as ships cleared to leave Ukraine
Dems push Biden climate, health priorities toward Senate OK
Dems' climate, energy, tax bill clears initial Senate hurdle
Transit woes mount for Boston's beleaguered subway riders
Shift in war's front seen as grain leaves Ukraine; plant hit
S&P 500   4,145.19
DOW   32,803.47
QQQ   321.75
China July exports rise, with trade surplus at record-high
pixel
Demand for grocery delivery cools as food costs rise
Shift in war's front seen as ships cleared to leave Ukraine
Dems push Biden climate, health priorities toward Senate OK
Dems' climate, energy, tax bill clears initial Senate hurdle
Transit woes mount for Boston's beleaguered subway riders
Shift in war's front seen as grain leaves Ukraine; plant hit
S&P 500   4,145.19
DOW   32,803.47
QQQ   321.75
China July exports rise, with trade surplus at record-high
pixel
Demand for grocery delivery cools as food costs rise
Shift in war's front seen as ships cleared to leave Ukraine
Dems push Biden climate, health priorities toward Senate OK
Dems' climate, energy, tax bill clears initial Senate hurdle
Transit woes mount for Boston's beleaguered subway riders
Shift in war's front seen as grain leaves Ukraine; plant hit
NASDAQ:GBT

Global Blood Therapeutics - GBT Stock Forecast, Price & News

$63.84
+15.85 (+33.03%)
(As of 08/5/2022 12:00 AM ET)
Add
Compare
Today's Range
$46.57
$73.02
50-Day Range
$22.30
$63.84
52-Week Range
$21.65
$73.02
Volume
13.98 million shs
Average Volume
1.37 million shs
Market Capitalization
$4.16 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$61.40

Global Blood Therapeutics MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.80 Rating Score
Upside/​Downside
3.8% Downside
$61.40 Price Target
Short Interest
Healthy
14.95% of Float Sold Short
Dividend Strength
N/A
Sustainability
-1.95
Upright™ Environmental Score
News Sentiment
0.14mentions of Global Blood Therapeutics in the last 14 days
Based on 22 Articles This Week
Insider Trading
Selling Shares
$34,335 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($4.65) to ($3.07) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.61 out of 5 stars

Medical Sector

1031st out of 1,283 stocks

Pharmaceutical Preparations Industry

486th out of 615 stocks

GBT stock logo

About Global Blood Therapeutics (NASDAQ:GBT) Stock

Global Blood Therapeutics, Inc., a biopharmaceutical company, engages in the discovery, development, and delivery of treatments for underserved patient communities with sickle cell disease (SCD). The company offers Oxbryta tablets, an oral, once-daily therapy for SCD. It also evaluates the safety and pharmacokinetics of single and multiple doses of Oxbryta in a Phase II a clinical trial of adolescent and pediatric patients with SCD. In addition, the company is developing its lead product candidate inclacumab, novel human monoclonal antibody, which is in Phase III a clinical trial to reduce the incidence of painful vaso-occlusive crises, and resulting hospital admissions; and GBT601, a hemoglobin polymerization inhibitor that is in Phase I development. It has a license and collaboration agreement with Syros Pharmaceuticals, Inc. to discover, develop, and commercialize therapies for SCD and beta thalassemia; and Sanofi S.A. to two early-stage research programs in SCD. Global Blood Therapeutics, Inc. was incorporated in 2011 and is headquartered in South San Francisco, California.

Global Blood Therapeutics Price Performance

Shares of Global Blood Therapeutics stock opened at $63.84 on Friday. The company has a quick ratio of 7.74, a current ratio of 8.52 and a debt-to-equity ratio of 4.34. The firm's 50-day moving average price is $31.23 and its 200 day moving average price is $30.78. Global Blood Therapeutics has a twelve month low of $21.65 and a twelve month high of $73.02.

Global Blood Therapeutics (NASDAQ:GBT - Get Rating) last released its earnings results on Wednesday, May 4th. The company reported ($1.26) earnings per share for the quarter, topping analysts' consensus estimates of ($1.29) by $0.03. Global Blood Therapeutics had a negative net margin of 146.82% and a negative return on equity of 129.74%. The business had revenue of $55.20 million for the quarter, compared to analyst estimates of $56.13 million. During the same period last year, the company posted ($1.21) EPS. The business's revenue was up 41.5% on a year-over-year basis. On average, research analysts expect that Global Blood Therapeutics will post -4.65 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several research firms have recently issued reports on GBT. JPMorgan Chase & Co. lowered their target price on shares of Global Blood Therapeutics from $39.00 to $36.00 and set a "neutral" rating on the stock in a research note on Tuesday, June 28th. Cantor Fitzgerald began coverage on shares of Global Blood Therapeutics in a research note on Thursday, April 28th. They set a "buy" rating and a $75.00 target price on the stock. Oppenheimer lowered their target price on shares of Global Blood Therapeutics from $86.00 to $71.00 in a research note on Thursday, May 5th. Wedbush set a $74.00 target price on shares of Global Blood Therapeutics in a research note on Monday, June 20th. Finally, StockNews.com raised shares of Global Blood Therapeutics from a "sell" rating to a "hold" rating in a research note on Thursday, May 5th. Three research analysts have rated the stock with a hold rating and eight have issued a buy rating to the company. According to data from MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus target price of $61.40.

Insiders Place Their Bets

In other Global Blood Therapeutics news, Director Philip A. Pizzo sold 1,260 shares of the firm's stock in a transaction that occurred on Tuesday, June 21st. The shares were sold at an average price of $27.25, for a total value of $34,335.00. Following the transaction, the director now directly owns 9,112 shares of the company's stock, valued at approximately $248,302. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Corporate insiders own 4.90% of the company's stock.

Receive GBT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Global Blood Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

GBT Stock News Headlines

Why Global Blood Therapeutics Stock Is Soaring Today
Stock Market Lower As Crude Oil Prices Fall Below $90
See More Headlines
Receive GBT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Global Blood Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

GBT Company Calendar

Last Earnings
11/04/2021
Today
8/07/2022
Next Earnings (Confirmed)
8/08/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:GBT
Fax
N/A
Employees
457
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$61.40
High Stock Price Forecast
$75.00
Low Stock Price Forecast
$31.00
Forecasted Upside/Downside
-3.8%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.80
Research Coverage
10 Analysts

Profitability

Net Income
$-303,090,000.00
Net Margins
-146.82%
Pretax Margin
-146.57%

Debt

Sales & Book Value

Annual Sales
$194.75 million
Book Value
$3.05 per share

Miscellaneous

Free Float
61,908,000
Market Cap
$4.16 billion
Optionable
Optionable
Beta
0.83

Key Executives

  • Dr. Ted W. Love M.D. (Age 63)
    Pres, CEO & Director
    Comp: $1.06M
  • Mr. Jeffrey S. Farrow (Age 60)
    CFO & Principal Accounting Officer
    Comp: $672.67k
  • Ms. Jung E. Choi (Age 52)
    Chief Bus. & Strategy Officer
    Comp: $645k
  • Mr. David L. Johnson (Age 53)
    Chief Commercial Officer
    Comp: $661.5k
  • Dr. Kim Smith-Whitley M.D. (Age 61)
    Exec. VP and Head of R&D
    Comp: $654k
  • Dr. David R. Phillips
    Founder & Advisor
  • Dr. Matthew P. Jacobson Ph.D.
    Founder & Advisor
  • Dr. Andrej Sali Ph.D.
    Founder & Advisor
  • Ms. Nazila Habibizad (Age 59)
    Exec. VP of Operations
  • Stephanie Yao
    Sr. Director of Corp. Communications & Investor Relations













GBT Stock - Frequently Asked Questions

Should I buy or sell Global Blood Therapeutics stock right now?

10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Global Blood Therapeutics in the last twelve months. There are currently 2 hold ratings and 8 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Global Blood Therapeutics stock.
View analyst ratings for Global Blood Therapeutics
or view top-rated stocks.

What is Global Blood Therapeutics' stock price forecast for 2022?

10 Wall Street analysts have issued 12 month price objectives for Global Blood Therapeutics' shares. Their GBT stock forecasts range from $31.00 to $75.00. On average, they expect Global Blood Therapeutics' share price to reach $61.40 in the next twelve months. This suggests that the stock has a possible downside of 3.8%.
View analysts' price targets for Global Blood Therapeutics
or view top-rated stocks among Wall Street analysts.

How has Global Blood Therapeutics' stock price performed in 2022?

Global Blood Therapeutics' stock was trading at $29.27 at the beginning of the year. Since then, GBT shares have increased by 118.1% and is now trading at $63.84.
View the best growth stocks for 2022 here
.

When is Global Blood Therapeutics' next earnings date?

Global Blood Therapeutics is scheduled to release its next quarterly earnings announcement on Monday, August 8th 2022.
View our earnings forecast for Global Blood Therapeutics
.

How can I listen to Global Blood Therapeutics' earnings call?

Global Blood Therapeutics will be holding an earnings conference call on Monday, August 8th at 4:30 PM Eastern. Interested parties can register for or listen to the call using this link.

How were Global Blood Therapeutics' earnings last quarter?

Global Blood Therapeutics, Inc. (NASDAQ:GBT) posted its earnings results on Thursday, November, 4th. The company reported ($1.13) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.10) by $0.03. The firm earned $52.05 million during the quarter, compared to analyst estimates of $53.69 million. Global Blood Therapeutics had a negative trailing twelve-month return on equity of 129.74% and a negative net margin of 146.82%. The company's revenue was up 41.1% compared to the same quarter last year. During the same quarter in the prior year, the business posted ($0.97) EPS.

What is Ted W. Love, M.D.'s approval rating as Global Blood Therapeutics' CEO?

13 employees have rated Global Blood Therapeutics CEO Ted W. Love, M.D. on Glassdoor.com. Ted W. Love, M.D. has an approval rating of 100% among Global Blood Therapeutics' employees. This puts Ted W. Love, M.D. in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Global Blood Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Global Blood Therapeutics investors own include Micron Technology (MU), NVIDIA (NVDA), Alibaba Group (BABA), Exelixis (EXEL), Pfizer (PFE), AbbVie (ABBV), Intel (INTC), Advanced Micro Devices (AMD), Gilead Sciences (GILD) and Block (SQ).

When did Global Blood Therapeutics IPO?

(GBT) raised $102 million in an initial public offering on Wednesday, August 12th 2015. The company issued 6,000,000 shares at a price of $16.00-$18.00 per share. Morgan Stanley and Goldman Sachs served as the underwriters for the IPO and Cowen and Company and Wedbush PacGrow were co-managers.

What is Global Blood Therapeutics' stock symbol?

Global Blood Therapeutics trades on the NASDAQ under the ticker symbol "GBT."

Who are Global Blood Therapeutics' major shareholders?

Global Blood Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Roosevelt Investment Group LLC (1.23%), Candriam S.C.A. (1.20%), EULAV Asset Management (0.58%), Mizuho Markets Americas LLC (0.29%), Assenagon Asset Management S.A. (0.26%) and Hennion & Walsh Asset Management Inc. (0.19%). Company insiders that own Global Blood Therapeutics stock include Dawn Svoronos, De Dominicis Robert, Deval L Patrick, Eric Fink, Jeffrey S Farrow, Joshua Lehrer-Graiwer, Lesley Ann Calhoun, Mark L Perry, Philip A Pizzo, Scott W Morrison, Ted W Love, Tricia Borga Suvari and Willie L Jr Brown.
View institutional ownership trends for Global Blood Therapeutics
.

How do I buy shares of Global Blood Therapeutics?

Shares of GBT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Global Blood Therapeutics' stock price today?

One share of GBT stock can currently be purchased for approximately $63.84.

How much money does Global Blood Therapeutics make?

Global Blood Therapeutics (NASDAQ:GBT) has a market capitalization of $4.16 billion and generates $194.75 million in revenue each year. The company earns $-303,090,000.00 in net income (profit) each year or ($4.87) on an earnings per share basis.

How many employees does Global Blood Therapeutics have?

Global Blood Therapeutics employs 457 workers across the globe.

How can I contact Global Blood Therapeutics?

Global Blood Therapeutics' mailing address is 171 OYSTER POINT BLVD SUITE 300, SOUTH SAN FRANCISCO CA, 94080. The official website for Global Blood Therapeutics is www.gbt.com. The company can be reached via phone at (650) 741-7700 or via email at investor@gbt.com.

This page (NASDAQ:GBT) was last updated on 8/7/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.